KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific SessionBusiness Wire • 02/07/23
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma ConferenceBusiness Wire • 02/03/23
KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment ThesisSeeking Alpha • 01/25/23
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to PresidentBusiness Wire • 01/05/23
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 MeetingBusiness Wire • 11/14/22
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary AngioedemaBusiness Wire • 10/31/22
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for SebetralstatBusiness Wire • 10/19/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALVPRNewsWire • 10/10/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of KalVista Pharmaceuticals, Inc. - KALVNewsfile Corp • 10/08/22
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership WorkshopBusiness Wire • 10/07/22
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap HeapInvestors Business Daily • 10/04/22
KalVista shares slide 26% premarket after company halts trial of treatment for hereditary angioedemaMarket Watch • 10/04/22
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary AngioedemaBusiness Wire • 10/04/22
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership WorkshopBusiness Wire • 09/30/22
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary AngioedemaBusiness Wire • 08/23/22
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema ConferenceBusiness Wire • 07/19/22
KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor ProgramBusiness Wire • 07/05/22